[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"minimally-invasive-surgical-technique\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:minimally-invasive-surgical-technique":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,87,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634059","minimaly-ivnasive-surgery-for-grade-iii-hemorrhoids-100634059",false,"NCT07534761","Minimaly Ivnasive Surgery for Grade III Hemorrhoids","Prospective Observational Study to Assess the Reproducibility of Minimally Invasive Surgery in Closed Excisional Hemorrhoidectomy: Phase 2A of theI DEAL Framework","Inclusion Criteria:\n\n* Age over 18 years\n* Grade III\u002FIV hemorrhoids\n* Indication for CEH surgery\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Acute hemorrhoidal disease (thrombosis)\n* Previous hemorrhoid surgery\n* Coexistence of anal fissure\n* Coexistence of perianal fistula\n* Coexistence of rectal or anal prolapse\n* Active inflammatory bowel disease\n* Active anal or colorectal cancer\n* Language barrier or difficulty in oral and\u002For written comprehension","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","1 Year","OBSERVATIONAL","Hemorrhoids are vascular-elastic structures of the anal canal that contribute to continence. Their enlargement and descent lead to symptoms such as rectal bleeding and the sensation of anal swelling, known as hemorrhoidal syndrome. In advanced cases (Goligher Grade III-IV), surgery is the only effective treatment. Closed excisional hemorrhoidectomy (CEH), based on the Ferguson technique, is one of the standard procedures. Although effective in the long term, it causes severe postoperative pain. Minimally invasive surgery (MIS) employs enhanced visualization devices to improve surgical precision and reduce tissue damage. While widely used in specialties with small surgical fields, it has not yet been explored in anal surgery. Its advantages include reduced tissue injury and improved healing, although it presents a learning curve and an initially longer surgical time. The IDEAL framework evaluates surgical innovations in five stages: Idea, Development, Exploration, Evaluation, and Long-Term Study. The IDEAL phase 2a is aimed at the optimization and technical definition of surgical innovation with a focus on continuous improvement based on real clinical practice, laying the foundation for broader and more rigorous subsequent studies.\n\nSince no previous studies on the application of MIS in CEH have been found, the investigators propose a study within Stage 2A of the IDEAL model to assess the reproducibility of this technique. The investigators believe its incorporation into closed excisional hemorrhoidectomy could result in less postoperative pain and faster patient recovery.",[25,26],"Hemorrhoidectomy","Minimally Invasive Surgical Technique",[28,25,29,30],"hemorrhoids grade III-IV","IDEAL stage 2A","minimally Invasive Surgical Technique","NOT_YET_RECRUITING","2026-04-16",{"date":34,"type":35},"2026-04-21","ACTUAL",{"date":37,"type":20},"2026-06-01",{"date":39,"type":20},"2027-12-01",{"name":41,"class":42},"Hospital Son Llatzer","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":68,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":43},"100588255","laparoscopic-versus-robot-assisted-left-sided-pancreatectomy-for-benign-and-pre-malignant-lesions-diploma-3-100588255","NCT06939023","Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3)","Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3): an International Multicenter Patient-blinded Randomized Controlled Trial","DIPLOMA-3","Inclusion Criteria:\n\n* Age at least 18 years;\n* Indication for elective left-sided pancreatectomy, either spleen-preserving or non-preserving (because of proven or suspected left-sided benign or premalignant disease);\n* Both robot-assisted and laparoscopic left-sided pancreatectomy are technically feasible for resection, according to the local treatment team;\n* Fit to undergo left-sided pancreatectomy according to the surgeon and anaesthesiologist;\n* Written informed consent\n\nExclusion Criteria:\n\n* Suspected pancreatic ductal adenocarcinoma;\n* Tumor or cyst larger than 8 cm;\n* Required resection or ablation of organs other than pancreas and spleen;\n* Tumor involvement or abutment of major vessels (celiac trunk, mesenteric artery or vena cava);\n* Pregnancy;\n* Body mass index \\>40 kg\u002Fm2;\n* Participation in another study with interference of study outcomes",{"count":53,"type":20},256,"INTERVENTIONAL",[56],"NA","The DIPLOMA-3 trial is an international, multicenter, patient-blinded randomized controlled trial comparing laparoscopic and robot-assisted left-sided pancreatectomy. Patients with an indication for elective left-sided pancreatecomy for benign or premalignant lesions in the body or tail of the pancreas and considered eligible will be randomized between laparoscopic and robot-assisted resection.",[59,60,61,62,63,64,65,26,66,67],"Pancreatectomy","Distal Pancreatectomy (DP)","Pancreatic Neoplasms","Pancreatic Adenoma","Pancreatic Cyst","Pancreatic Cystadenoma","Surgery","Minimally Invasive Distal Pancreatectomy","Minimally Invasive Surgery",[69,70,71,72,73,74,75,76],"pancreas surgery","left-sided pancreatectomy","distal pancreatectomy","minimally invasive surgery","robot-assisted pancreatectomy","left pancreatectomy","robotic pancreatectomy","laparoscopic pancreatectomy","RECRUITING","2025-08-28",{"date":80,"type":35},"2025-09-04",{"date":82,"type":35},"2025-06-01",{"date":84,"type":20},"2028-06-01",{"name":86,"class":42},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":54,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":43},"100601337","robot-assisted-versus-open-lateral-pancreaticojejunostomy-for-the-treatment-of-symptomatic-chronic-pancreatitis-panacotta-100601337","NCT07109180","Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOTTA)","Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOTTA): a Multicenter Randomized Controlled Trial","PANACOTTA","Inclusion Criteria:\n\n* At least 18 years old\n* Indication for (extended or partial) lateral pancreaticojejunostomy as agreed during multidisciplinary team meeting based on symptomatic chronic pancreatitis (i.e. morphine dependent pain or recurrent acute flares of pancreatitis, at least 3 episodes per year) and a dilated pancreatic duct of ≥ 5 mm, with a non-enlarged pancreatic head \\\u003C 40 mm\n* Confirmed CP, according to the M-ANNHEIM diagnostic Criteria24\n* Eligible for both an robot-assisted and open approach\n* Obtained written informed consent\n\nExclusion Criteria:\n\n* Suspected or confirmed current pancreatic cancer\n* ASA classification ≥ 4\n* Other painful conditions aside from CP, with pain difficult to discriminate from CP pain\n* Prior pancreatic surgery\n* Pregnancy",{"count":96,"type":20},28,[56],"PANACOTTA is a multicenter randomized controlled trial including patients with symptomatic chronic pancreatitis and a dilated main pancreatic duct to either robot-assisted or open lateral pancreaticojejunostomy. The PANACOTTA trial will assess the post-operative quality of recovery following robot-assisted versus open lateral pancreaticojejunostomy.",[100,65,26,101,102,67,103],"Chronic Pancreatitis","Robot Surgica","Robot Surgery","Pancreaticojunostomy","2025-07-31",{"date":106,"type":35},"2025-08-07",{"date":108,"type":35},"2025-04-16",{"date":110,"type":20},"2026-12-31",{"name":86,"class":42},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":54,"phases":121,"briefSummary":122,"conditions":123,"keywords":129,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":43},"100569432","efficacy-of-the-entire-papilla-preservation-technique-with-and-without-the-use-of-l-prf-as-a-regenerative-material-for-the-treatment-of-infrabony-defects-100569432","NCT06694168","Efficacy of the Entire Papilla Preservation Technique With and Without the Use of L-PRF as a Regenerative Material for the Treatment of Infrabony Defects","Efficacy of the Entire Papilla Preservation Technique With and Without the Use of L-PRF as a Regenerative Material for the Treatment of Infrabony Defects: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients diagnosed with periodontal disease (loss of interproximal clinical attachment loss in 2 non-adjacent teeth or clinical attachment loss of ≥3mm associated with a PD \\>3 mm in two or more teeth) will be included.\n* After re-evaluation (6 weeks after non-surgical periodontal therapy) presented residual probing depths equal to or greater than 6 mm.\n* Residual pocket is associated with interproximal intrabony periodontal defects of at least 2 walls, with a depth ≥ 3 mm and an angulation ≤ 40º determined on a periapical radiograph.\n\nExclusion Criteria:\n\n* Patients with an underlying decompensated pathology such as diabetes and hypertension.\n* Patients taking medications that interfere with the healing process such as bisphosphonates.\n* Patients with diseases that alter bone metabolism such as osteoporosis.\n* Pregnant or breastfeeding women.",{"count":120,"type":20},30,[56],"The goal of this clinical trial is to evaluate the efficacy of using L-PRF (leukocyte and platelet rich fibrin clot) as an autologous filling material in conjunction with the EPP (entire papilla preservation) technique for the treatment of interproximal intraosseous periodontal defects, compared to the same technique without L-PRF regarding clinical periodontal parameters and obtained radiographic parameters. It will also report possible postoperative complications and evaluate postoperative sensitivity. The main questions it aims to answer is:\n\n• What is the effectiveness of LPR-F in conjunction with a complete papilla preservation (EPP) technique for the treatment of intrabony periodontal defects in CESA (health care center) patients in terms of clinical and radiographic periodontal parameters compared to the use of the same technique without L-PRF?\n\nA non-randomized controlled clinical trial will be conducted on patients at CESA of the Universidad de los Andes. In 30 patients, 30 periodontal defects associated with a pocket with probing depths equal to or greater than 6 mm will be treated using the complete papilla preservation technique, either with L-PRF filling or without any filling material, assigned randomly to each intervention (15 participants in each group). Researchers will evaluate clinical and radiographic parameters at baseline and 6 months post-surgery. Patients will report their level of pain 24 hours and 7 days after surgery.",[124,26,125,126,127,128],"Periodontal Regeneration","Platelet Rich Fibrin","Microsurgery","Periodontal Intrabony Defect","Periodontal Disease",[130,131,126,132,133,134,135,136],"Periodontitis","Guided Tissue Regeneration","Bone Regeneration","Treatment Outcome","Intrabony defect","minimally invasive surgical technique","Entire papilla preservation","2024-11-20",{"date":139,"type":35},"2024-11-25",{"date":141,"type":35},"2024-08-27",{"date":143,"type":20},"2026-06-30",{"name":145,"class":42},"Universidad de los Andes, Chile"]